Efficacy and Safety of a Dietary Supplement on Hair Growth and Hair Health in Female With Acute Telogen Effluvium

Inclusion criteria

• Good general health
• Caucasian ethnicity
• All hair type included
• Transient acute telogen effluvium (duration less than 6 months) due to fatigue, seasonal change, deficiency of vitamins and minerals, stress, change or imbalance of normal daily routing, or emotional stress
• Subjects having a positive pull test result
• Subjects with minimum hair length of 6/7 cm
• Subjects who stopped any anti hair loss treatment at least 3 months prior the study
• Subjects agreeing not to take any treatment (oral or topic) able to interfere with the hair growth, diameter or fall during the whole study duration
• Willingness not to dye/blench hair during the 2 weeks preceding each visit
• Willingness not to cut hair for all the study length
• Subjects registered with health social security or health social insurance
• Subjects having signed their written Informed Consent form (ICF) and Privacy Policy for their participation in the study and a photograph authorization
• Subjects able to understand the language used in the investigation centre and the information given
• Subjects able to comply with the protocol and follow protocol constraints and specific requirements
• Willingness to use during all the study period only the product to be tested
• Willingness not to use similar products that could interfere with the product to be tested
• Willingness to not vary the normal daily routine (i.e. lifestyle, physical activity, diet etc.)
• Subjects under effective contraception (oral/not oral) if women of childbearing potential; not expected to be changed during the trial

Exclusion criteria

• Subjects who do not meet the inclusion criteria
• Subject is taking part or planning to participate to another clinical study in the same or in another investigation centre
• Subject who is deprived of freedom by administrative or legal decision or under guardianship
• Subject admitted in a sanitary or social facilities
• Subject who is planning a hospitalization during the study
• Subjects under treatment with food supplements which could interfere with the functionality of the product under study
• Subject has participated in another clinical study with anti-hair loss product or treatment within the last 24 weeks before the inclusion visit
• Subject breastfeeding, pregnant or not willing to take necessary precautions to avoid pregnancy during the study (if women of childbearing potential)
• Subject has started or changed oestrogen-progesterone contraception or hormonal treatment, within the 3 months prior to the study or foreseeing it for the duration of the study
• Subject having an acute, chronic or progressive illness liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
• Subjects under radiotherapy, chemotherapy at any time
• Subjects under locally pharmacological/non-pharmacological treatment applied on the area of interest monitored during the test
• Subject having food disorders
• Subject who has any other hair disorder or hair disease (female pattern hair loss, any type of alopecia…)
• Subject having excessive and/or fluctuating hair shedding for more than 6 months
• History or clinical signs of hyperandrogenaemia
• Systemic treatment affecting the hair growth taken for more than 4 consecutive weeks during the last 24 weeks before inclusion visit
• Systemic or local androgenetic alopecia treatment or product, taken or applied (Minoxidil, Aminexil, Finasteride, Dutasteride, cosmetic solution or capsules with vitamin B, zinc, caffeine…) for more than 4 consecutive weeks during the last 24 weeks before the inclusion visit
• Any hair care product applied on the scalp between the last shampoo and the inclusion visit (e.g. gel, hairspray, wax, foam…)
• Scalp surgery (hair transplants, laser) at any time.
• Not menopausal women